GILD
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F2861073&ei=n4aaUoHNENOs0AHkzAE&usg=AFQjCNGY2E0x5B-1hIQZge7Q8yc7IrAMZw
Gilead Sciences Inc Announces Phase 2 Results For Sofosbuvir-Based Regimens In Hepatitis C Patients Before And After Liver Transplantation
Saturday, 2 Nov 2013 09:01am EDT
Gilead Sciences Inc announced results from two Phase 2 studies evaluating an all-oral treatment regimen of the investigational once-daily nucleotide analogue sofosbuvir plus ribavirin (RBV) for both the prevention and treatment of recurrent chronic hepatitis C virus (HCV) infection among patients who undergo liver transplantation. The findings will be presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2013) in Washington, D.C. In a study conducted among pre-transplant HCV patients (Study 2025), up to 48 weeks of sofosbuvir/RBV therapy was administered. Among patients with undetectable HCV (
